{"organizations": [], "uuid": "09b0a00916ac03df1cc92fea6dce0846074d2329", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-announces/brief-protalix-biotherapeutics-announces-final-dosing-of-last-patient-in-phase-ii-clinical-trial-of-oprx-106-idUSASB0C5X5", "country": "US", "domain_rank": 408, "title": "Protalix Biotherapeutics Announces Final Dosing Of Last Patient In Phase II Clinical Trial Of OPRX-106", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.993, "site_type": "news", "published": "2018-02-15T20:13:00.000+02:00", "replies_count": 0, "uuid": "09b0a00916ac03df1cc92fea6dce0846074d2329"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-protalix-biotherapeutics-announces/brief-protalix-biotherapeutics-announces-final-dosing-of-last-patient-in-phase-ii-clinical-trial-of-oprx-106-idUSASB0C5X5", "ord_in_thread": 0, "title": "Protalix Biotherapeutics Announces Final Dosing Of Last Patient In Phase II Clinical Trial Of OPRX-106", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "protalix biotherapeutics inc", "sentiment": "negative"}, {"name": "protalix biotherapeutics", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "  Updated 5 minutes ago BRIEF-Protalix Biotherapeutics Announces Final Dosing Of Last Patient In Phase II Clinical Trial Of OPRX-106 Reuters Staff 1 Min Read Feb 15 (Reuters) - Protalix Biotherapeutics Inc: * PROTALIX BIOTHERAPEUTICS ANNOUNCES FINAL DOSING OF LAST PATIENT IN PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS * PROTALIX BIOTHERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE RESULTS FROM PHASE II CLINICAL STUDY OF OPRX-106 BY END OF MARCH 2018  ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T20:13:00.000+02:00", "crawled": "2018-02-15T14:21:45.008+02:00", "highlightTitle": ""}